Payment overview · 2025
General Payments
$116.23
6 reported records · 3 companies
Healthcare provider profile · identity verified
Brian C Bai, MD
Allopathic & Osteopathic Physicians|Family Medicine · OXNARD, CA · NPI 1144424102
Verified facts
What the public records show
CMS Open Payments records show Brian C Bai, MD received $116.23 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.51 | 38.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.09 | 37.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.63 | 24.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $116.23 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $28.63 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 669 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 144 |
| Losartan Potassium | Losartan Potassium | 372 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 84 |
| Metformin Hcl | Metformin Hcl | 311 | 105 |
| Gabapentin | Gabapentin | 250 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 66 |
| Spironolactone | Spironolactone | 224 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 62 |
| Valsartan | Valsartan | 168 | 49 |
| Famotidine | Famotidine | 141 | 42 |
| Lisinopril | Lisinopril | 137 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 35 |
| Azelastine Hcl | Azelastine Hcl | 124 | 39 |
| Farxiga | Dapagliflozin Propanediol | 123 | 30 |
| Chlorthalidone | Chlorthalidone | 122 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 36 |
| Ozempic | Semaglutide | 119 | 27 |
| Alendronate Sodium | Alendronate Sodium | 115 | 43 |
| Omeprazole | Omeprazole | 115 | 28 |
| Finasteride | Finasteride | 112 | 42 |
| Glipizide Er | Glipizide | 111 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 34 |
| Ezetimibe | Ezetimibe | 95 | 31 |
| Metformin Hcl Er | Metformin Hcl | 95 | 32 |
| Jardiance | Empagliflozin | 93 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 29 |
| Carvedilol | Carvedilol | 80 | 25 |
| Torsemide | Torsemide | 80 | 34 |
| Sertraline Hcl | Sertraline Hcl | 76 | 24 |
| Mounjaro | Tirzepatide | 70 | 17 |
| Donepezil Hcl | Donepezil Hcl | 59 | 21 |
| Allopurinol | Allopurinol | 58 | 20 |
| Furosemide | Furosemide | 58 | 17 |
| Telmisartan | Telmisartan | 58 | 23 |
| Clonazepam | Clonazepam | 55 | 17 |
| Eliquis | Apixaban | 54 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 30 |
| Benazepril Hcl | Benazepril Hcl | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 18 |
| Olanzapine | Olanzapine | 37 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 17 |
| Kerendia | Finerenone | 36 | suppressed |
| Azithromycin | Azithromycin | 34 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 13 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Lidocaine | Lidocaine | 23 | suppressed |
| Eplerenone | Eplerenone | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | 11 |
| Erythromycin | Erythromycin Base | 19 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Ursodiol | Ursodiol | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116.23 · 6 records | Novo Nordisk Inc | Cologuard Collection Kit, Ozempic, PAXLOVID, Rybelsus, The Cologuard Plus Collection Kit, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error